Ahmed Bezza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed Bezza has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Ihsane Hmamouchi
Faculty of Medicine, Health Sciences Research Center (CReSS), International University of Rabat (UIR), Rabat, Morocco
3 shared publications - Imad Ghozlani
Faculty of Medicine and Pharmacy, University Ibn Zohr, Rheumatology, Agadir, Morocco
3 shared publications - Radouane Niamane
Department of Rheumatology, Military Hospital Avicenne, Mohammed VI University Hospital, Marrakech, Morocco
3 shared publications - Abdellah El Maghraoui
Rheumatology Office, Mohamed V University, Rabat, Morocco
2 shared publications - Fadoua Allali
Department of Rheumatology B, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco
2 shared publications - Hasna Hassikou
Military Hospital Moulay Ismail, Hassan II University Hospital, Rheumatology, Meknes, Morocco
2 shared publications
Latest Publications
- 9 January 2026
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 22
Factors Determining the Switch of the First Biological Treatment in Spondyloarthritis: Data from the RBSMR Registry
Introduction: Despite the substantial progress made in the therapeutic management of spondylarthritis (SpA) after the advent of biotherapy, some patients still undergo, for various reasons, therapeutic switches to an alternative biological agent. This study aimed to identify the factors leading to the switch from the initial biological treatment in patients with SpA, with a view toward tailoring the prescription to the patient's profile. Methods: Adult patients (aged >18 years) with spondylarthritis treated with biotherapy were enrolled in a cohort derived from a national historical-prospective multicenter registry between June 2017 and January 2019. The selection was based on the ASAS criteria, and patients were assessed every six months with a planned three-year follow-up. Baseline demographics and disease characteristics at the time of biologic therapy initiation were collected. Factors determining the switch to first bDMARDs were identified through univariate and multivariate logistic regression, reporting odds ratios (OR) with 95% confidence intervals (CI). Results: A total of 194 SpA patients were included. By the end of follow-up, 46 patients (23.71%) had switched to a second biologic agent (TNFα inhibitor or secukinumab). This switch was significantly associated with: advanced age (p = 0.030), higher Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (p = 0.024), and the absence of specific comorbidities, including heart disease and stroke (p = 0.011 for both). Conclusion: The new bio-medications have considerably improved the prognosis of patients suffering from chronic inflammatory rheumatism, necessitating regular monitoring to detect events that could lead to a treatment switch. In our study, we identified factors associated with therapeutic switching, particularly advanced age, a history of corticosteroid therapy, and specific comorbidities. These findings highlight potential risk factors; however, further studies with larger cohorts and immunogenicity data are required before firm clinical recommendations can be made.
- 9 January 2026
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 22
Factors Determining the Switch of the First Biological Treatment in Spondyloarthritis: Data from the RBSMR Registry
Introduction: Despite the substantial progress made in the therapeutic management of spondylarthritis (SpA) after the advent of biotherapy, some patients still undergo, for various reasons, therapeutic switches to an alternative biological agent. This study aimed to identify the factors leading to the switch from the initial biological treatment in patients with SpA, with a view toward tailoring the prescription to the patient's profile. Methods: Adult patients (aged >18 years) with spondylarthritis treated with biotherapy were enrolled in a cohort derived from a national historical-prospective multicenter registry between June 2017 and January 2019. The selection was based on the ASAS criteria, and patients were assessed every six months with a planned three-year follow-up. Baseline demographics and disease characteristics at the time of biologic therapy initiation were collected. Factors determining the switch to first bDMARDs were identified through univariate and multivariate logistic regression, reporting odds ratios (OR) with 95% confidence intervals (CI). Results: A total of 194 SpA patients were included. By the end of follow-up, 46 patients (23.71%) had switched to a second biologic agent (TNFα inhibitor or secukinumab). This switch was significantly associated with: advanced age (p = 0.030), higher Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (p = 0.024), and the absence of specific comorbidities, including heart disease and stroke (p = 0.011 for both). Conclusion: The new bio-medications have considerably improved the prognosis of patients suffering from chronic inflammatory rheumatism, necessitating regular monitoring to detect events that could lead to a treatment switch. In our study, we identified factors associated with therapeutic switching, particularly advanced age, a history of corticosteroid therapy, and specific comorbidities. These findings highlight potential risk factors; however, further studies with larger cohorts and immunogenicity data are required before firm clinical recommendations can be made.
- Open Access
- 9 October 2025
- Published by Science Publishing Group in Science Journal of Clinical Medicine
- Vol. 14 (4) , 95-100
Difficult-to-treat Spondyloarthritis: What Are the Associated Factors
Introduction: There have been significant advances in the treatment of spondylarthritis (SpA) in recent years. Despite these advances, there is still a proportion of patients who experience multiple changes in biologic, which may correspond to difficult-to-treat spondylarthritis (SPA DaT). Unlike rheumatoid arthritis, there is no consensus definition for this concept. The aim of our study is to determine the prevalence of multi-switchers with spondylarthritis, identify their characteristics, and analyse the number and reasons for switching in a Moroccan population. Patients and methods: This is a comparative cross-sectional study that included patients with SpA diagnosed according to the 2009 ASAS criteria admitted to our department for targeted treatment. Sociodemographic data, comorbidities, and clinical, paraclinical, and therapeutic characteristics were collected for each patient. Multi-switchers who had received at least two biologics were considered to be SpA DaT. Their prevalence was estimated, and a comparison was made with a control group of non-multi-switchers (SpA-non-DaT). Results: Two hundred and ten patients were included, 56.2% of whom were men, 63% with a long average disease duration. The prevalence of multi-switchers was 32.7%. Compared to the control group, patients in the DaT group were predominantly female (53.6% versus 39%, p=0.04), had more axial involvement (76.8% versus 91.5%, p=0.003) and peripheral joint involvement (88.4% versus 67.4%, p= 0.001) and associated fibromyalgia (33.3% versus 66.7%, p = 0.980), CsDMARD use (97.1% versus 31.9%, p= < 0.001), and corticosteroid use (34.8% versus 11.3%, p= < 0.001). Disease activity, BASDAI, ASDAS and CRP at the start of biotherapy were higher in the SPA DaT group (BASDAI: 21.8% versus 20.6%, p=0.08), (ASDAS: 46.4% versus 54.6%, p = 0.03), BASFI (27.5% versus 41.8% p=0.04) CRP (: 14.19±4.73 mg/l versus 13.7±2.1 mg/l, p = 0.01). Similarly, the time between diagnosis and use of the first biologic was longer (4 [2.25–6] years versus 3 [1–4] years, p = 0.03). All patients in the DaT group had received anti-TNFα, and 22.9% had received anti-IL17. Analysing switches between biologics in this difficult-to-treat group, the first switch was linked to primary failure in 59% of cases, secondary failure in 29% of cases, and an adverse effect in 12% of cases. In the second switch, primary and secondary failure were observed in 64% and 33% of cases, respectively, and adverse effects in 3%. Regarding the third switch, 83% had primary failure and 17% had secondary failure. Conclusion: This study reveals a significant prevalence of patients with multiple treatment changes in the Moroccan population, highlighting the need for a larger patient sample to better define this condition.
- 9 October 2025
- Published by Science Publishing Group in Science Journal of Clinical Medicine
- Vol. 14 (4) , 95-100
Open AccessDifficult-to-treat Spondyloarthritis: What Are the Associated Factors
Introduction: There have been significant advances in the treatment of spondylarthritis (SpA) in recent years. Despite these advances, there is still a proportion of patients who experience multiple changes in biologic, which may correspond to difficult-to-treat spondylarthritis (SPA DaT). Unlike rheumatoid arthritis, there is no consensus definition for this concept. The aim of our study is to determine the prevalence of multi-switchers with spondylarthritis, identify their characteristics, and analyse the number and reasons for switching in a Moroccan population. Patients and methods: This is a comparative cross-sectional study that included patients with SpA diagnosed according to the 2009 ASAS criteria admitted to our department for targeted treatment. Sociodemographic data, comorbidities, and clinical, paraclinical, and therapeutic characteristics were collected for each patient. Multi-switchers who had received at least two biologics were considered to be SpA DaT. Their prevalence was estimated, and a comparison was made with a control group of non-multi-switchers (SpA-non-DaT). Results: Two hundred and ten patients were included, 56.2% of whom were men, 63% with a long average disease duration. The prevalence of multi-switchers was 32.7%. Compared to the control group, patients in the DaT group were predominantly female (53.6% versus 39%, p=0.04), had more axial involvement (76.8% versus 91.5%, p=0.003) and peripheral joint involvement (88.4% versus 67.4%, p= 0.001) and associated fibromyalgia (33.3% versus 66.7%, p = 0.980), CsDMARD use (97.1% versus 31.9%, p= < 0.001), and corticosteroid use (34.8% versus 11.3%, p= < 0.001). Disease activity, BASDAI, ASDAS and CRP at the start of biotherapy were higher in the SPA DaT group (BASDAI: 21.8% versus 20.6%, p=0.08), (ASDAS: 46.4% versus 54.6%, p = 0.03), BASFI (27.5% versus 41.8% p=0.04) CRP (: 14.19±4.73 mg/l versus 13.7±2.1 mg/l, p = 0.01). Similarly, the time between diagnosis and use of the first biologic was longer (4 [2.25–6] years versus 3 [1–4] years, p = 0.03). All patients in the DaT group had received anti-TNFα, and 22.9% had received anti-IL17. Analysing switches between biologics in this difficult-to-treat group, the first switch was linked to primary failure in 59% of cases, secondary failure in 29% of cases, and an adverse effect in 12% of cases. In the second switch, primary and secondary failure were observed in 64% and 33% of cases, respectively, and adverse effects in 3%. Regarding the third switch, 83% had primary failure and 17% had secondary failure. Conclusion: This study reveals a significant prevalence of patients with multiple treatment changes in the Moroccan population, highlighting the need for a larger patient sample to better define this condition.
- Open Access
- 10 September 2025
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 63 (4) , 244-250
What are the characteristics of paradoxical effects in the Biotherapies Registry of the Moroccan Society of Rheumatology?
Introduction: The main objective of our study was to assess the prevalence of paradoxical reactions in patients with chronic inflammatory rheumatism treated with biologic drugs, while secondary objectives were to determine the type of paradoxical reactions and to investigate associated factors.Material and methods: We conducted a descriptive cohort study using 36-month frozen data from the RBSMR registry. This is a registry promoted by the Moroccan Society of Rheumatology, including patients treated for rheumatoid arthritis (RA) or spondyloarthritis treated with a biologic drug. The paradoxical reaction was defined by the appearance of a pathology that could be treated by biological drugs. We investigated the prevalence of paradoxical reactions, and the factors associated with their occurrence. Statistical analysis was performed using JAMOVI software.Results: We analyzed 440 patients in the RBSMR. Paradoxical reactions were found in 19 pa- tients (4.6%). The mean time to onset of paradoxical manifestations was 30 weeks (1–144 weeks). Uveitis was the most frequent paradoxical reaction, found in 9 patients, followed by psoriasis in 7 patients, and then pyoderma gangrenosum, lichen, and granulomatous dermatitis in only 1 patient each. These paradoxical effects were found predominantly in men (57.9% of cases). Etanercept was the most prescribed biologic, in 52.6% of patients with paradoxical reactions, followed by adalimumab in 21.1%, golimumab in 15.8%, and secukinumab in 5.3%. Permanent discontinuation of biological treatment was recommended for all patients. In univariate analysis, the occurrence of a paradoxical effect was related to sex (p = 0.05) and to disease activity in patients with RA (p = 0.04).Conclusions: Our study suggests that there is a low prevalence of paradoxical effects in our population. However, these are reactions that need to be identified and investigated to improve the management of our patients with chronic inflammatory rheumatism.
- 10 September 2025
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 63 (4) , 244-250
Open AccessWhat are the characteristics of paradoxical effects in the Biotherapies Registry of the Moroccan Society of Rheumatology?
Introduction: The main objective of our study was to assess the prevalence of paradoxical reactions in patients with chronic inflammatory rheumatism treated with biologic drugs, while secondary objectives were to determine the type of paradoxical reactions and to investigate associated factors.Material and methods: We conducted a descriptive cohort study using 36-month frozen data from the RBSMR registry. This is a registry promoted by the Moroccan Society of Rheumatology, including patients treated for rheumatoid arthritis (RA) or spondyloarthritis treated with a biologic drug. The paradoxical reaction was defined by the appearance of a pathology that could be treated by biological drugs. We investigated the prevalence of paradoxical reactions, and the factors associated with their occurrence. Statistical analysis was performed using JAMOVI software.Results: We analyzed 440 patients in the RBSMR. Paradoxical reactions were found in 19 pa- tients (4.6%). The mean time to onset of paradoxical manifestations was 30 weeks (1–144 weeks). Uveitis was the most frequent paradoxical reaction, found in 9 patients, followed by psoriasis in 7 patients, and then pyoderma gangrenosum, lichen, and granulomatous dermatitis in only 1 patient each. These paradoxical effects were found predominantly in men (57.9% of cases). Etanercept was the most prescribed biologic, in 52.6% of patients with paradoxical reactions, followed by adalimumab in 21.1%, golimumab in 15.8%, and secukinumab in 5.3%. Permanent discontinuation of biological treatment was recommended for all patients. In univariate analysis, the occurrence of a paradoxical effect was related to sex (p = 0.05) and to disease activity in patients with RA (p = 0.04).Conclusions: Our study suggests that there is a low prevalence of paradoxical effects in our population. However, these are reactions that need to be identified and investigated to improve the management of our patients with chronic inflammatory rheumatism.
- Open Access
- 27 May 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 9 (1) , 1-13
Real-world evidence of biological treatments in rheumatoid arthritis and spondyloarthritis in Morocco: results of the RBSMR registry
Regional variability in the effectiveness and safety of biologic therapies for rheumatoid arthritis (RA) and spondyloarthritis (SpA) underscores the need for comprehensive assessment. The aim of this study was to provide real-world evidence of the effectiveness and the safety of biologic for RA, SpA including psoriatic arthritis, in the daily clinical practice. RBSMR registry was a multicenter, cohort study conducted in 10 university departments of rheumatology. The study included RA and SpA patients receiving biotherapy, either as an initiation or ongoing treatment, and investigated for 3 years. The statistical analysis was performed using JAMOVI software (T student test, Mann–Whitney U test, Chi-squared test, Fisher’s exact test, Paired T test and Wilcoxon test). 223 RA and 194 SpA were eligible. After 3 years of follow-up, DAS28 CRP (3.6 ± 1.4 versus 5.8 ± 1.0 at baseline) and ASDAS CRP (1.8[1-2.4] versus 3.5[2.5–4.4] at baseline) significantly improved; 13.8% of RA patients achieved remission based on DAS28 CRP and 20.1% of SpA patients achieved remission based on ASDAS CRP. Overall, 163 and 126 adverse events were reported in RA and SpA patients respectively. Infections were the most frequently reported events with an incidence of 11.8 and 13.4/100 patients-year in RA and SpA respectively. Total incidence rate of tuberculosis was 0.80 patient/100 patients-year. The RBSMR registry provides real-world insights into the effectiveness of biologics in the practice of rheumatology for RA and SpA patients in Morocco. It underscores the critical need for continued vigilance in monitoring and addressing adverse events, with a particular focus on tuberculosis infection.
- 27 May 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 9 (1) , 1-13
Open AccessReal-world evidence of biological treatments in rheumatoid arthritis and spondyloarthritis in Morocco: results of the RBSMR registry
Regional variability in the effectiveness and safety of biologic therapies for rheumatoid arthritis (RA) and spondyloarthritis (SpA) underscores the need for comprehensive assessment. The aim of this study was to provide real-world evidence of the effectiveness and the safety of biologic for RA, SpA including psoriatic arthritis, in the daily clinical practice. RBSMR registry was a multicenter, cohort study conducted in 10 university departments of rheumatology. The study included RA and SpA patients receiving biotherapy, either as an initiation or ongoing treatment, and investigated for 3 years. The statistical analysis was performed using JAMOVI software (T student test, Mann–Whitney U test, Chi-squared test, Fisher’s exact test, Paired T test and Wilcoxon test). 223 RA and 194 SpA were eligible. After 3 years of follow-up, DAS28 CRP (3.6 ± 1.4 versus 5.8 ± 1.0 at baseline) and ASDAS CRP (1.8[1-2.4] versus 3.5[2.5–4.4] at baseline) significantly improved; 13.8% of RA patients achieved remission based on DAS28 CRP and 20.1% of SpA patients achieved remission based on ASDAS CRP. Overall, 163 and 126 adverse events were reported in RA and SpA patients respectively. Infections were the most frequently reported events with an incidence of 11.8 and 13.4/100 patients-year in RA and SpA respectively. Total incidence rate of tuberculosis was 0.80 patient/100 patients-year. The RBSMR registry provides real-world insights into the effectiveness of biologics in the practice of rheumatology for RA and SpA patients in Morocco. It underscores the critical need for continued vigilance in monitoring and addressing adverse events, with a particular focus on tuberculosis infection.